Skip to content

A clinical research about the serum exosome-derived circRNAs function as molecular phynotype biomarker for the boardline resectable pancreatic cancer

A clinical research about the serum exosome derived circRNAs function as molecular phynotype biomarker for the boardline resectable pancreatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018038
Enrollment
Unknown
Registered
2018-08-27
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Interventions

Gold Standard:Pathology
Index test:Serum&#32

Sponsors

Union Hospital, Tongji Medical College, HUST
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The primary diagnosis is pancreatic cancer; 2. The evaluation of CT and MRI is boardline resectable pancreatic cancer; 3. The patient should be received radical Whipple resection, and the resection margin is validated as negative; 4. The function of liver,kidney,lung and heart is not disfunction; 5. There is no contraindication for operation; 6. The patient and relative agree with the clincal trail and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. The patient has received neoadjavent therapy before; 2. The patient has admitted the other clinical trail in recent 3 months; 3. The patient has obvious disfunction of liver,kidney,lung and heart; 4. The patient is not suitable for clincal trail.

Design outcomes

Primary

MeasureTime frame
Progression of tumor;Serum CA19-9;

Secondary

MeasureTime frame
Overall survival;Progression free survival;Qulity of life;

Countries

China

Contacts

Public ContactGANG ZHAO

Union Hospital, Tongji Medical College, HUST

gangzhao@aliyun.com+86 13797044969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026